Ngā hua rapu kaituhi

1

Emerging immunotherapies for renal cell carcinoma mā Bernard Escudier

I whakaputaina 2012

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
2

Axitinib for the Management of Metastatic Renal Cell Carcinoma mā Bernard Escudier, Martin Gore

I whakaputaina 2011

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
3

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up mā Bernard Escudier, Vesa Kataja

I whakaputaina 2010

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
4

Nivolumab in renal cell carcinoma: latest evidence and clinical potential mā Camille Mazza, Bernard Escudier, Laurence Albigès

I whakaputaina 2016

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
5

Sequential therapy in renal cell carcinoma mā Bernard Escudier, M. Gross Goupil, Christophe Massard, Karim Fizazi

I whakaputaina 2009

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
6

Heat and Moisture Exchanger vs Heated Humidifier during Long-Term Mechanical Ventilation mā Benoît Misset, Bernard Escudier, Daniel Rivara, Bernard Leclercq, Gérard Nitenberg

I whakaputaina 1991

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
7

A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma mā Chrystelle Brignone, Bernard Escudier, Caroline Grygar, Manon Marcu, Frédéric Triebel

I whakaputaina 2009

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
8

Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma mā Robert J. Motzer, Bernard Escudier, Andrew Gannon, Robert A. Figlin

I whakaputaina 2016

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
9

Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma mā Hassan Izzedine, Lisa Derosa, Gwénaël Le Teuff, Laurence Albigès, Bernard Escudier

I whakaputaina 2015

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
10

Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma mā S. Antoun, Vickie E. Baracos, Laura Birdsell, Bernard Escudier, Michael B. Sawyer

I whakaputaina 2010

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
11

Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib mā G. Mickisch, M. Gore, Bernard Escudier, Giuseppe Procopio, Stefan Walzer, Mark Nuijten

I whakaputaina 2009

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
12

Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma mā Robert J. Motzer, Bernard Escudier, Thomas Powles, Christian Scheffold, Toni K. Choueiri

I whakaputaina 2018

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
13

Hypoxia Promotes Tumor Growth in Linking Angiogenesis to Immune Escape mā Salem Chouaı̈b, Yosra Messai, Sophie Couvé, Bernard Escudier, Meriem Hasmim, Muhammad Zaeem Noman

I whakaputaina 2012

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
14

Prognostic factors for survival in patients with brain metastases from renal cell carcinoma mā St�phane Culine, Mohamed Békradda, Andrew Kramar, Annie Rey, Bernard Escudier, Jean-Pierre Droz

I whakaputaina 1998

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
15

Metastatic renal cell carcinoma management mā Flávio Lobo Heldwein, Bernard Escudier, Gordon K. Smyth, Carlos Ary Vargas Souto, Guy Vallancien

I whakaputaina 2009

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
16

Insulin and IGFs in renal cancer risk and progression mā Wojciech Solarek, Anna M. Czarnecka, Bernard Escudier, Zofia F. Bielecka, Fei Lian, Cezary Szczylik

I whakaputaina 2015

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
17

TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma mā Laurence Albigès, Philippe Barthélémy, Marine Gross‐Goupil, Sylvie Négrier, Michael N. Needle, Bernard Escudier

I whakaputaina 2020

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
18

Phosphostim-Activated γδ T Cells Kill Autologous Metastatic Renal Cell Carcinoma mā Emilie Viey, Gaëlle Fromont, Bernard Escudier, Yannis Morel, Sylvie Da Rocha, Salem Chouaı̈b, Anne Caignard

I whakaputaina 2005

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
19

$Neovastat (Æ-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels$

Neovastat (Æ-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels mā Gerald Batist, François Patenaude, P. Champagne, David Croteau, Carey Levinton, C. Hariton, Bernard Escudier, É. Dupont

I whakaputaina 2002

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
20

Metastatic Renal Cell Carcinoma Treated with Sunitinib: Early Evaluation of Treatment Response Using Dynamic Contrast-Enhanced Ultrasonography mā Nathalie Lassau, Serge Koscielny, Laurence Albigès, L. Chami, Baya Benatsou, Mohamed Chébil, Alain Roche, Bernard Escudier

I whakaputaina 2010

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:

Ngā hua rapu - Bernard Escudier

Emerging immunotherapies for renal cell carcinoma mā Bernard Escudier

Axitinib for the Management of Metastatic Renal Cell Carcinoma mā Bernard Escudier, Martin Gore

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up mā Bernard Escudier, Vesa Kataja

Nivolumab in renal cell carcinoma: latest evidence and clinical potential mā Camille Mazza, Bernard Escudier, Laurence Albigès

Sequential therapy in renal cell carcinoma mā Bernard Escudier, M. Gross Goupil, Christophe Massard, Karim Fizazi

Heat and Moisture Exchanger vs Heated Humidifier during Long-Term Mechanical Ventilation mā Benoît Misset, Bernard Escudier, Daniel Rivara, Bernard Leclercq, Gérard Nitenberg

A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma mā Chrystelle Brignone, Bernard Escudier, Caroline Grygar, Manon Marcu, Frédéric Triebel

Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma mā Robert J. Motzer, Bernard Escudier, Andrew Gannon, Robert A. Figlin

Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma mā Hassan Izzedine, Lisa Derosa, Gwénaël Le Teuff, Laurence Albigès, Bernard Escudier

Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma mā S. Antoun, Vickie E. Baracos, Laura Birdsell, Bernard Escudier, Michael B. Sawyer

Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib mā G. Mickisch, M. Gore, Bernard Escudier, Giuseppe Procopio, Stefan Walzer, Mark Nuijten

Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma mā Robert J. Motzer, Bernard Escudier, Thomas Powles, Christian Scheffold, Toni K. Choueiri

Hypoxia Promotes Tumor Growth in Linking Angiogenesis to Immune Escape mā Salem Chouaı̈b, Yosra Messai, Sophie Couvé, Bernard Escudier, Meriem Hasmim, Muhammad Zaeem Noman

Prognostic factors for survival in patients with brain metastases from renal cell carcinoma mā St�phane Culine, Mohamed Békradda, Andrew Kramar, Annie Rey, Bernard Escudier, Jean-Pierre Droz

Metastatic renal cell carcinoma management mā Flávio Lobo Heldwein, Bernard Escudier, Gordon K. Smyth, Carlos Ary Vargas Souto, Guy Vallancien

Insulin and IGFs in renal cancer risk and progression mā Wojciech Solarek, Anna M. Czarnecka, Bernard Escudier, Zofia F. Bielecka, Fei Lian, Cezary Szczylik

TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma mā Laurence Albigès, Philippe Barthélémy, Marine Gross‐Goupil, Sylvie Négrier, Michael N. Needle, Bernard Escudier

Phosphostim-Activated γδ T Cells Kill Autologous Metastatic Renal Cell Carcinoma mā Emilie Viey, Gaëlle Fromont, Bernard Escudier, Yannis Morel, Sylvie Da Rocha, Salem Chouaı̈b, Anne Caignard

Neovastat (Æ-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels mā Gerald Batist, François Patenaude, P. Champagne, David Croteau, Carey Levinton, C. Hariton, Bernard Escudier, É. Dupont

Metastatic Renal Cell Carcinoma Treated with Sunitinib: Early Evaluation of Treatment Response Using Dynamic Contrast-Enhanced Ultrasonography mā Nathalie Lassau, Serge Koscielny, Laurence Albigès, L. Chami, Baya Benatsou, Mohamed Chébil, Alain Roche, Bernard Escudier

Ngā utauta rapu:

Ngā marau whai pānga